CBIZ (CBZ) Q4 2025 earnings review
Marcum is Digested: The Narrative Pivots to Free Cash Flow
CBIZ capped off a transformational 2025 by delivering $2.76B in total revenue (+52% YoY) and $3.61 in Adjusted EPS, reflecting the successful absorption of the massive Marcum acquisition. However, the investment narrative is pivoting sharply. With the acquisition lapping, revenue growth is decelerating to a guided 2-5% for 2026. The bull case now hinges entirely on cash generation and operational execution. Management is guiding for Free Cash Flow to accelerate massively to $280M at the midpoint (a ~60% YoY jump), which is fueling aggressive share repurchases ($168M executed, 5M shares newly authorized). While the core Financial Services segment is expanding margins, the Benefits & Insurance segment stalled in Q4, highlighting lingering macro pressure on discretionary spending.
🐂 Bull Case
Guidance of $270M-$290M in FCF for 2026 represents a ~60% conversion of Adjusted EBITDA. This allows CBIZ to aggressively deleverage while supporting its new 5-million-share repurchase authorization.
The Marcum integration is nearly complete with synergies tracking ahead of plan. This provides a clear path to expand Adjusted EBITDA margins even as top-line growth normalizes.
🐻 Bear Case
A 2026 revenue growth guide of 2-5% is a severe deceleration from historical mid-to-high single-digit organic growth, suggesting pricing power fatigue and soft volumes in discretionary advisory.
The B&I segment grew a meager 0.2% YoY in Q4, struggling against a soft Property & Casualty market and dragging down the overall growth profile.
⚖️ Verdict: ⚪
Neutral-to-Bullish. The anemic 2-5% organic growth outlook is a legitimate concern that caps multiple expansion. However, the sheer volume of free cash flow being generated and deployed into buybacks provides a very strong floor for the stock.
Key Themes
The Organic Growth Reality Check
Management's press release touted 'continued improvement in revenue growth,' but the data contradicts this optimistic narrative. 2026 revenue guidance of $2.8B-$2.9B implies just 2% to 5% YoY growth. This is a massive deceleration from the 7.1% legacy organic growth posted in 2024. It indicates that without the M&A engine running, the company is facing real headwinds in pricing realization and volume expansion.
Benefits & Insurance Segment Stalls
The B&I segment has become a clear laggard. While Financial Services grew 22.6% YoY in Q4 (aided by the Marcum comp), B&I revenue was completely stable at $91.3M vs $91.2M in 24Q4 (+0.2%). Previous quarters flagged a soft Property & Casualty market and the departure of Southeast producers; this Q4 print shows those issues have not been resolved.
Synergies Eclipsing Expectations
Management confirmed that Marcum integration milestones are largely complete and synergies are tracking 'ahead of plan.' Previous quarters cited a target of $50M+ in synergies. By standardizing tools and consolidating real estate, CBIZ is successfully extracting costs to defend margins against the softer revenue environment.
Structural Cost Transformation via AI and Offshoring
The company is executing on a major structural shift by leveraging its new scale to build offshore capabilities in India and the Philippines, alongside deploying its proprietary CBIZ Vertical Vector AI. This transition from highly-paid domestic headcount to AI-assisted offshore resources is a vital driver to hit the 2026 Adjusted EBITDA target.
Industry Vertical Rollout Complete
CBIZ completed the rollout of its 12 priority industry groups. By packaging accounting, tax, and advisory services under unified industry leaders, the company is attempting to unlock cross-selling opportunities across the legacy Marcum base. Early traction was noted with 'several notable wins' in cross-serving.
Macro Pressures on Advisory Services
The underlying macro narrative remains a drag. Previous quarters cited delayed M&A activity and a frozen SEC capital markets environment dampening discretionary advisory spend. The cautious 2026 top-line guidance strongly implies management does not expect these macro-sensitive, project-based services to experience a V-shaped recovery in the near term.
Other KPIs
Improved from a -$90.7 million loss in 24Q4. The optics of a massive Q4 loss are a known feature of CBIZ's seasonality, amplified significantly by the Marcum acquisition. November and December are traditionally loss-making months for accounting firms before the busy tax season begins in Q1.
Market volatility creates accounting noise for CBIZ. Q4 operating expenses included $3.2M related to the DCP, which was fully offset by $3.7M in Other Income. Excluding these non-cash mark-to-market adjustments, the adjusted Q4 operating loss was -$81.4M.
CBIZ shifted aggressively from debt paydown to equity reduction, retiring 2.5 million shares. The Board authorized an additional 5 million shares in February 2026, signaling that management views the stock as undervalued and intends to deploy its accelerating free cash flow toward repurchases.
Guidance
Decelerating violently. This represents just 2% to 5% growth over FY25's $2.76B. With the Marcum acquisition officially lapped, the company is reverting to an organic baseline that looks notably weaker than its historical mid-single-digit standard.
Decelerating. The midpoint of $3.80 represents a 5.2% YoY growth rate, a steep drop from the 79.6% growth achieved in 2025. It suggests that margin expansion and share buybacks are doing the heavy lifting while organic top-line growth struggles.
Stable. Midpoint of $455M implies less than 2% growth over FY25's $447M. If synergies are tracking ahead of plan, this flattish EBITDA guide suggests underlying pricing or wage pressure in the core business.
Accelerating. This is the crown jewel of the guidance. A jump from $175.5M to $280M (midpoint) implies ~60% YoY growth. This represents roughly 60% conversion of Adjusted EBITDA, validating the cash-generative nature of the business model post-integration.
Key Questions
Organic Growth Baseline
With FY26 revenue guided to just 2-5% growth, how much of this is driven by pricing versus volume? Are you modeling zero recovery in the discretionary M&A and SEC advisory markets?
Benefits & Insurance Trajectory
The B&I segment was perfectly flat in Q4 YoY. What specific actions are being taken to return this segment to historical growth rates, and has the P&C market pricing bottomed?
Capital Allocation Priority
With FCF guided to $280M and a new 5M share repurchase authorization in place, has the priority definitively shifted from deleveraging the balance sheet to buying back stock?
EBITDA Guidance Conservatism
You noted that integration synergies are tracking ahead of plan and offshoring is transforming the cost structure, yet the Adjusted EBITDA guide implies less than 2% growth. Is this conservatism, or are there new cost headwinds offsetting the synergies?